Nonpapillary renal cell carcinoma

Researchers are testing a new cell therapy called ADI-270 in adults with clear cell renal cell carcinoma that has come back or stopped responding to standard treatments. ADI-270 uses engineered gamma-delta T cells that carry a chimeric receptor to seek out and attack cancer cells…

This early-phase study aimed to test a new vaccine called KSD-201 in people with advanced clear cell renal cell carcinoma whose cancer had stopped responding to standard treatments. The vaccine uses the patient's own immune cells to try to fight the cancer. However, the trial was…

This early-phase study tests a personalized vaccine made from unique markers in a person's kidney tumor. The vaccine is given along with two immune-boosting drugs (Poly-ICLC and ipilimumab) to see if it is safe and can train the immune system to fight the cancer. The trial includ…

This study tests a combination of two drugs (fruquintinib and serplulimab) as the first treatment for people with a rare type of kidney cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors or slow the disease. About 39 adults will t…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This study tests whether adding a third drug (relatlimab) to a standard two-drug combination (nivolumab and ipilimumab) works better for advanced kidney cancer that hasn't been treated before. About 15 adults with stage IV clear cell kidney cancer will receive either the three-dr…

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …

This early-stage study tests a new treatment called ALLO-316 for people with advanced or spreading clear cell kidney cancer who have already tried standard therapies like checkpoint inhibitors and VEGF inhibitors. The treatment uses specially designed immune cells from a donor to…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This study tests whether adding entinostat to high-dose aldesleukin (interleukin-2) can help shrink tumors in people with metastatic kidney cancer. About 47 adults with clear cell renal cell carcinoma that has spread will receive both drugs. The goal is to find the safest dose an…

This study tests whether combining newer immunotherapy drugs with a standard targeted therapy (axitinib) can safely control advanced kidney cancer. About 199 adults with untreated, advanced clear-cell renal cell carcinoma will receive one of three drug combinations. The main goal…

This phase 3 trial tests whether the drug pazopanib can delay or prevent kidney cancer from coming back in patients who have had all visible tumors removed by surgery. 129 adults with clear cell kidney cancer that had spread are randomly assigned to take either pazopanib or a pla…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 participants will receive either the combination or cabozantinib alone. The goal is to see if the …

This study tests a drug called adavosertib in adults with advanced solid tumors that have a missing or broken SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.

This study is testing experimental combinations of drugs for people with advanced kidney cancer (clear cell type) that has gotten worse after initial treatment. The goal is to see if these combinations are safe and can shrink tumors. About 370 participants will be enrolled in thi…

This clinical trial is testing several new combinations of drugs for people with advanced kidney cancer that has spread. The study includes about 400 participants who have not had any prior treatment for their advanced disease. The goal is to see if these combinations are safe an…

This phase 3 trial is testing whether a combination of the experimental drug XL092 and the immunotherapy nivolumab can help people with advanced non-clear cell kidney cancer live longer without their disease worsening. Participants have not received prior treatment for their adva…

This early-phase trial tests whether adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) is safe and can improve treatment for advanced kidney cancer. About 31 people with metastatic clear-cell or sarcomatoid kidney cancer will receive the co…

This study tests whether combining three drugs—ipilimumab, nivolumab, and ciforadenant—can better control advanced kidney cancer that has spread. About 50 adults with clear cell renal cell carcinoma who have not had prior treatment will receive the combo. The main goal is to see …

This trial tests a combination of two drugs—anlotinib (a pill that blocks blood vessel growth to tumors) and sintilimab (an IV immunotherapy that helps the immune system attack cancer cells)—as a first treatment for people with advanced non-clear cell renal cell carcinoma, a rare…

This early-phase trial tests a new treatment called IVS-3001, which uses a patient's own immune cells (T cells) engineered to target a protein called HLA-G found on some solid tumors. The study involves 31 adults with advanced solid tumors that have not responded to standard trea…

This early-phase study tests whether giving immunotherapy drugs (nivolumab alone or with bevacizumab or ipilimumab) before surgery is safe for people with advanced kidney cancer that has spread. About 104 participants will receive one of these treatments before their tumor is rem…

This study tests whether adding an experimental drug (PF-04518600) that boosts the immune system to the standard drug axitinib can help control advanced kidney cancer better than axitinib alone. About 62 adults whose cancer has spread and who have already tried an immune checkpoi…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in 200 adults with advanced or spreading solid tumors, including certain ovarian, cervical, endometrial, bladder, and kidney cancers. The goal is to see if the drug can shrink tumors or stop them from growing. Part…

This study tests a combination of two drugs, cadonilimab and lenvatinib, in 28 adults with advanced clear cell kidney cancer that worsened after initial immunotherapy. The goal is to see if the combo can shrink tumors or slow disease progression. Participants receive treatment un…

This phase 3 trial tests whether adding belzutifan to standard pembrolizumab after kidney cancer surgery can delay or prevent the cancer from coming back. About 1800 participants with clear cell renal cell carcinoma are randomly assigned to receive either belzutifan plus pembroli…

This phase 3 trial compares the experimental drug belzutifan to the standard drug everolimus in 755 people with advanced kidney cancer that has worsened after prior treatments. The goal is to see if belzutifan can better delay cancer growth and improve survival. Participants take…

This early-phase study tests a new immune therapy for people with advanced kidney or bladder cancer. Researchers take a person's own natural killer cells, train them in the lab to better recognize cancer, and give them back along with a protein that boosts immune activity. The ma…

This phase 2 trial is testing whether the drug cabozantinib can shrink tumors in 22 people with advanced kidney cancer before they have surgery. The goal is to see if the drug reduces tumor size enough to improve surgical outcomes and delay cancer return. Participants take caboza…

This study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…

This study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with locally advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the combination for 12 weeks before their operation. The go…

This study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is …

This study tests whether combining two drugs—serplulimab and fruquintinib—can prevent kidney cancer from returning after surgery in people with a rare, aggressive type called non-clear cell renal cell carcinoma. About 40 adults at high risk of recurrence will receive both drugs f…

This phase II trial tests whether adjusting doses of two drugs—pembrolizumab (Keytruda) and axitinib (Inlyta)—based on tumor response can better control advanced kidney cancer. The study aims to enroll 75 adults with clear cell renal cell carcinoma that has spread. The trial is c…

This study tests two drugs, pazopanib and bevacizumab, given one after the other in people with advanced kidney cancer that has spread. The goal is to find the best dose and see how well the combination works. About 51 patients who have not had prior treatment will take part. The…

This phase 2 study tests a combination of two drugs—nivolumab (an immunotherapy) and a radioactive antibody called 177Lu-girentuximab—in people with advanced clear cell kidney cancer that has the CAIX protein. The goal is to find the safest dose and see if the combination shrinks…

This early-stage study tests a new drug called NYM096 in people with advanced clear cell kidney cancer that has spread. The study has two parts: first, using a low dose to see if it can light up tumors on scans, and second, giving higher doses to see if it can shrink tumors and f…

This study tests whether adding a supplement called Seleno-L Methionine to two standard drugs (axitinib and pembrolizumab) is safe and effective for people with advanced or spreading clear cell kidney cancer. About 55 participants will receive the combination therapy. The goal is…

This study tests if a subcutaneous (under-the-skin) injection of the drug nivolumab works as well as the standard intravenous (IV) infusion for people with advanced or metastatic clear cell renal cell carcinoma, a type of kidney cancer. About 681 participants who have already rec…

This phase 2 trial tests whether taking the drug axitinib for 8 weeks before surgery can shrink kidney tumors in people with clear cell renal cell carcinoma. The goal is to make partial nephrectomy (removing only the tumor) possible for patients whose tumors are too complex for t…

This phase II trial tests three different immunotherapy combinations given before surgery to patients with high-risk clear cell kidney cancer. The goal is to see if these drugs can shrink the tumor and reduce the risk of the cancer returning. About 69 participants will receive ei…

This early-phase trial tests a new treatment called AB-2100 for people with advanced or metastatic clear-cell renal cell carcinoma that has come back after standard treatments. AB-2100 is made from the patient's own immune cells, which are modified in the lab to better recognize …

This program gives patients with kidney masses access to a radioactive tracer called 89Zr-DFO-girentuximab, which is used with a PET/CT scan to detect clear cell renal cell carcinoma (a common kidney cancer) without surgery. The tracer attaches to a protein (CAIX) often found on …

This study aimed to see if a special PET/CT scan using a radioactive tracer called piflufolastat F 18 could better detect whether clear cell renal cell carcinoma (a type of kidney cancer) has spread. Researchers planned to enroll adults with suspected or high-risk metastatic dise…

This study looks at whether measuring certain autoantibodies in the blood can help diagnose kidney cancer earlier and predict how the disease will progress. Researchers will analyze data from 400 patients to build a predictive model. The goal is to personalize treatment and avoid…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study aims to understand why kidney tumors in people with VHL syndrome can be different from each other. Researchers will use advanced imaging, multiple biopsies, and lab-grown tumor models to map these differences. The goal is to learn more about the disease, not to test a …

This study looks at 500 kidney cancer patients to see if CT scans and machine learning can predict levels of a protein called HIF-2α. The goal is to better identify which patients might benefit from a targeted drug called Belzutifan, reducing unnecessary treatments and improving …